Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma

Melanoma is molecularly and structurally heterogeneous, with some tumor cells existing under hypoxic conditions. Our cell growth assays showed that under controlled hypoxic conditions, BRAF(V600E) melanoma cells rapidly became resistant to vemurafenib. By employing both a three-dimensional (3D) spheroid model and a two-dimensional (2D) hypoxic culture system to model hypoxia in vivo, we identified upregulation of HGF/MET signaling as a major mechanism associated with vemurafenib resistance as compared with 2D standard tissue culture in ambient air. We further confirmed that the upregulation of HGF/MET signaling was evident in drug-resistant melanoma patient tissues and mouse xenografts. Pharmacologic inhibition of the c-Met/Akt pathway restored the sensitivity of melanoma spheroids or 2D hypoxic cultures to vemurafenib. Mol Cancer Ther; 15(10); 2442–54. ©2016 AACR.

[1]  S. Pastoreková,et al.  Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib. , 2016, Molecular medicine reports.

[2]  Yuhua Lin,et al.  HGF expression induced by HIF‐1α promote the proliferation and tube formation of endothelial progenitor cells , 2015, Cell biology international.

[3]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[4]  Chang S. Chan,et al.  Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD , 2014, Oncotarget.

[5]  M. Mazzone,et al.  Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment , 2014, Oncogene.

[6]  Jason Li,et al.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. , 2014, Cancer discovery.

[7]  R. Salgia,et al.  Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt Signaling in Hepatocyte Growth Factor (HGF)-mediated Lamellipodia Formation, Reactive Oxygen Species (ROS) Generation, and Motility of Lung Endothelial Cells* , 2014, The Journal of Biological Chemistry.

[8]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive , 2014, Clinical Cancer Research.

[9]  F. Briest,et al.  PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms , 2014, Theranostics.

[10]  A. Weeraratna,et al.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.

[11]  J. Sosman,et al.  Impact of MET expression on outcome in BRAFV600E/K advanced melanoma , 2013, Histopathology.

[12]  S. Corso,et al.  Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. , 2013, Cancer discovery.

[13]  T. Ochiya,et al.  Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β , 2013, Scientific Reports.

[14]  T. Kondo,et al.  Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system , 2013, Proteomics.

[15]  Fabio Fumarola,et al.  Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma , 2013, Clinical Cancer Research.

[16]  Chandrani Chattopadhyay,et al.  Association of activated c‐Met with NRAS‐mutated human melanomas , 2012, International journal of cancer.

[17]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[18]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[19]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[20]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[21]  Hideo Namiki,et al.  The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. , 2011, Biomaterials.

[22]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[23]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. E. Vincent,et al.  Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer , 2011, British Journal of Cancer.

[25]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[26]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[27]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[28]  Kazuya Negishi,et al.  Phosphorescent light-emitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals , 2010, BiOS.

[29]  D. Feng,et al.  Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1 , 2009, Molecular Biology Reports.

[30]  P. Bendinelli,et al.  Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. , 2009, Carcinogenesis.

[31]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[32]  P. Várnai,et al.  c-Met Must Translocate to the Nucleus to Initiate Calcium Signals*♦ , 2008, Journal of Biological Chemistry.

[33]  Kenneth M. Yamada,et al.  Modeling Tissue Morphogenesis and Cancer in 3D , 2007, Cell.

[34]  M. Westphal,et al.  Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migration , 2007, International journal of cancer.

[35]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[36]  L. Broemeling,et al.  Tumor iNOS predicts poor survival for stage III melanoma patients , 2006, International journal of cancer.

[37]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[38]  Jens Overgaard,et al.  Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer , 2004, Acta oncologica.

[39]  J. Reis-Filho,et al.  Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas , 2003, Oncology.

[40]  C. Koch,et al.  Prognostic significance of tumor oxygenation in humans. , 2003, Cancer letters.

[41]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[42]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[43]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[44]  M. Dewhirst,et al.  Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[46]  Peter Vaupel,et al.  Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? , 2013, Advances in experimental medicine and biology.

[47]  O. Cuvillier,et al.  Hypoxia, therapeutic resistance, and sphingosine 1-phosphate. , 2013, Advances in cancer research.

[48]  John W Haycock,et al.  3D cell culture: a review of current approaches and techniques. , 2011, Methods in molecular biology.